Guided Therapeutics to Report Fourth Quarter and Year End 2012 Results and Hold Conference Call

Wed Mar 20, 2013 4:05pm EDT

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130320:nBw206541a

NORCROSS, Ga.--(Business Wire)--
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and
painless testing platform that uses biophotonics for the early detection of
disease, today announced that it is scheduled to report financial results for
its fourth quarter and year ended December 31, 2012 on Wednesday, March 27,
2013, after the market closes. 

Guided Therapeutics will hold a conference call at 11:00 a.m. EDT on Thursday,
March 28, 2013, to discuss its financial results and corporate developments.
Interested parties are invited to listen to the call live over the Internet at
http://www.guidedinc.com/investors.htm or http://www.viavid.net. The live call
is also available by dialing (888) 438-5535 or for international callers (719)
785-1765. 

A replay of the teleconference will be available on
http://www.guidedinc.com/investors.htm. A replay will also be available, until
April 4, 2013, by dialing (877) 870-5176 or for international callers (858)
384-5517, and using pin number 7470435. 

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is developing a rapid and
painless testing platform for the early detection of disease based on its
patented biophotonic technology that utilizes light to detect disease at the
cellular level. The Company`s first planned product is the LuViva Advanced
Cervical Scan, a non-invasive device used to detect cervical disease instantly
and at the point of care. In a multi-center clinical trial, with women at risk
for cervical disease, the technology was able to detect cervical cancer up to
two years earlier than conventional modalities, according to published reports.
Guided Therapeutics is also developing a non-invasive test for the early
detection of esophageal cancer using the technology platform. For more
information, visit: www.guidedinc.com. 

The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational
device and is limited by federal law to investigational use. LuViva, the wave
logo and "Early detection, better outcomes" are registered trademarks owned by
Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject areas
discussed in this news release that are not historical or current facts deal
with potential future circumstances and developments. The discussion of such
matters and subject areas is qualified by the inherent risks and uncertainties
surrounding future expectations generally and also may materially differ from
Guided Therapeutics` actual future experience involving any of or more of such
matters and subject areas. Such risks and uncertainties include those related to
the early stage of products in development, the uncertainty of market acceptance
of products, the uncertainty of development or effectiveness of distribution
channels, the intense competition in the medical device industry, the
uncertainty of capital to develop products, the uncertainty of regulatory
approval of products, dependence on licensed intellectual property, as well as
those that are more fully described from time to time under the heading "Risk
Factors" in Guided Therapeutics` reports filed with the SEC, including Guided
Therapeutics` Annual Report on Form 10-K for the fiscal year ended December 31,
2011, and subsequent quarterly reports.

Investors:
Cameron Associates
Alison Ziegler, 212-554-5469
or
Guided Therapeutics
Bill Wells, 770-242-8723 Ext. 241 

Copyright Business Wire 2013